SCHEMBL2841125

SCHEMBL2841125

O=C(NO)C(c1ccccc1)c1ccc(NS(=O)(=O)c2ccc(Cl)s2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
HDAC4 P56524 3/20 0.51
HDAC7 Q8WUI4 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
LMNA P02545 4/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
BMP1 P13497 1/20 0.47
CASP3 P42574 2/20 0.46
SENP8 Q96LD8 2/20 0.46
SENP7 Q9BQF6 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20490310 0.90 SMN1; SMN2 (0.51) MAPTHDAC4HDAC7HDAC5HDAC3
SCHEMBL2847555 0.84 HDAC4 (0.49) MAPTHDAC4HDAC7HDAC5HDAC3
SCHEMBL2841655 0.81 TDP1 (0.61) HDAC4HDAC7HDAC5HDAC3HDAC1
SCHEMBL20490430 0.81 MEN1 (0.58) MAPTHDAC4HDAC7HDAC5HDAC3
SCHEMBL2844092 0.79 HDAC4 (0.74) HDAC4HDAC7HDAC5HDAC3HDAC1
SCHEMBL2842555 0.79 ALDH1A1 (0.57) MAPTHDAC4HDAC7HDAC5HDAC3
SCHEMBL2839414 0.79 HDAC4 (0.63) MAPTHDAC4HDAC7HDAC5HDAC3
SCHEMBL7573063 0.79 MAPT (0.63) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL2841736 0.76 PGR (0.63) MAPTHDAC4HDAC7HDAC5HDAC3
SCHEMBL2840269 0.75 HDAC4 (0.64) MAPTHDAC4HDAC7HDAC5HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP claimed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP claimed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US claimed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO claimed
EP-2139850-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2018-09-12 EP disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
EP-2139850-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-01-06 EP disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 MAPT 1533/4885HDAC4 10/4885HDAC7 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.